Study: mRNA vaccines perform better against COVID-19 variants of concern AstraZeneca, BNT162b2 (Pfizer and BioNTech), Coronavirus Disease (COVID-19) Pandemic, COVID-19 Studies, COVID-19 Vaccines, Covid-19 Variants, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Messenger RNA (mRNA) Vaccines, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pandemics, Peer-Reviewed Analysis, Pfizer, PLOS Medicine, R&D, SARS-CoV-2 virus, Therapeutics, Vaxzevria (previously COVID-19 Vaccine AstraZeneca) In a peer-reviewed study published May 17 in PLOS Medicine, scientists found that mRNA-based COVID-19 vaccines were superior to adenovirus vector-based ones across major variants of the SARS-CoV-2 virus. Read more May 18, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/05/BioSpaceCOVIDvaccine.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-05-18 11:42:342022-05-18 11:47:36Study: mRNA vaccines perform better against COVID-19 variants of concern